FDA Issues Draft Guidance on Exclusivity Periods for Biologics
August 2014
The US Food and Drug Administration “the FDA” has issued draft guidance on exclusivity periods for Biological Products. The guidance is intended to assist sponsors who are developing biological products as well as sponsors of biologics license applications and represents another step towards the first approval of a biosimilar product in the USA.
Find out more